Ivan Kairatov is a seasoned biopharma expert with an extensive background in research and development, specializing in the intersection of technology and clinical innovation. With years of experience navigating the complexities of the drug approval pipeline, he has become a leading voice on how digital transformation can address the modern bottlenecks of the industry. In this conversation, we explore the evolving landscape of clinical oversight, discussing the transition from manual data review to AI-driven workflows and the critical importance of maintaining regulatory trust in a data-heavy era.
Phase III trials now average 3.6 million data points, a staggering increase from a decade ago. How does this massive volume disrupt traditional manual review, and what specific metrics can organizations use to demonstrate that AI-assisted signal detection maintains the necessary rigor for highly regulated environments?
The sheer volume of data has reached a breaking point where traditional manual review is no longer a viable strategy for maintaining speed or quality. When you consider that data points have tripled in just ten years, the cognitive load on human reviewers leads to inevitable delays and potential oversights in identifying safety signals. To prove rigor in these highly regulated environments, organizations must focus on metrics like signal-to-noise ratios and the time elapsed from data entry to anomaly detection. We also look at the consistency of AI behavior over time to ensure that the system is behaving predictably and providing a defensible rationale for every flagged data point. It’s about moving away from the $200 billion annual R&D spend that produces stagnant approval numbers and using technology to actually move the needle.
Clinical programmers frequently face bottlenecks with manual listing generation. How does automating these low-level tasks shift their daily focus toward high-value work, and what practical steps should teams take to ensure medical monitors access critical insights without the typical delays?
Automating listing generation removes one of the most persistent hurdles in the clinical workflow, allowing programmers to step away from the tedious “low-level” work of data preparation. Instead of spending weeks formatting spreadsheets, they can focus on high-value tasks like complex pattern analysis and improving the overall data strategy. To ensure medical monitors get what they need, teams should implement automated review workflows that provide real-time access to filtered, high-priority data. This eliminates the “waiting game” that usually characterizes the relationship between data management and medical oversight. By integrating AI-assisted tools directly into the clinical ecosystem, we ensure that the people making the big decisions are working with the most current information available, rather than data that is weeks old.
A “human in command” approach requires clinicians to monitor AI performance over time. How should teams establish guardrails for overriding automated outputs, and what specific audit trails are required to prove the reproducibility and transparency of these decisions during regulatory inspections?
The “human in command” philosophy is non-negotiable because clinical judgment and contextual interpretation must remain the final authority in any trial. Guardrails are established by creating a system where every AI-generated output is treated as a recommendation that requires a human signature to validate or override. For regulatory inspections, you need an audit trail that captures not just the final decision, but the data-grounded evidence the AI presented and the specific reason why a human expert chose a different path. This level of transparency ensures that the process is fully reproducible and that the sponsor can demonstrate total accountability. We have to show regulators that the AI is an assistant, not a black-box decision-maker, by maintaining a documented history of every intervention.
Global guidelines are shifting toward risk-based quality management rather than universal data verification. How can machine learning identify the highest-risk data points or problematic sites, and what protocol changes are needed to implement this targeted oversight effectively across multi-site trials?
Machine learning excels at pattern recognition across millions of data points, allowing us to pivot from 100 percent source data verification to a much more surgical, risk-proportional approach. By analyzing historical performance and real-time anomalies, algorithms can flag specific sites that show suspicious data patterns or protocol deviations that a human eye might miss across dozens of global locations. To implement this, protocols need to be rewritten to define “quality by design” and establish clear thresholds for when a site requires an intensive audit versus routine monitoring. This shift allows us to focus our most expensive and expert resources on the areas that actually jeopardize the trial’s integrity. It’s a smarter way to work that aligns perfectly with the updated ICH E6(R3) guidelines regarding sponsor accountability and continuous oversight.
Choosing between building internal AI tools or adopting purpose-built solutions involves complex trade-offs. What are the hidden resource demands of internal validation and documentation, and how can a vendor-supported model improve lifecycle management and long-term compliance?
Many organizations underestimate the “hidden” costs of building internal tools, which include not just the initial coding, but the massive burden of validation, documentation, and staying compliant with shifting global regulations. When you build internally, you are solely responsible for the tool’s entire lifecycle, which can drain resources away from your core mission of drug development. A vendor-supported model, like what we see with purpose-built solutions, transfers much of that technical and regulatory maintenance to experts who specialize in inspection readiness. This model offers predictable costs and ensures that the software is always updated to meet the latest standards, such as the FDA’s initiatives for agentic AI. Ultimately, it allows the sponsor to retain regulatory responsibility while leveraging a platform that is already proven to be transparent and traceable.
What is your forecast for AI in clinical oversight?
I believe we are moving toward a future where “real-time oversight” is the standard, rather than a goal we strive for. In the coming years, I expect AI to move beyond simple signal detection and into predictive modeling that can forecast potential trial failures or safety issues months before they manifest in the data. We will see a more seamless integration where human-in-command AI becomes a background utility, much like a pilot’s autopilot system—constantly monitoring, correcting minor drifts, and alerting the human expert only when a critical decision is required. This evolution will finally help the industry overcome the “more spend, fewer approvals” paradox by making the path from data collection to regulatory submission faster, safer, and significantly more transparent.
